By Bernadette Toner and Turna Ray
SAN FRANCISCO — A Novartis official said yesterday that the company has identified a genetic marker that it plans to market as a companion diagnostic for a COX-2 inhibitor that was previously withdrawn from several non-US markets due to liver toxicity issues.
Registering provides access to this and other free content.
Already have an account?Login Now.
A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.
As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.
In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.